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Summary.-A mouse monoclonal cell line (L1) was produced by fusing the mouse
myeloma P3X63/Ag8 with CD2F1 spleen cells immunized with a highly immunogenic
subline of L1210 leukaemia (Li210/DTIC). A very few positive clones (1%) were
isolated and one of these was chosen for detailed study. The monoclonal antibody
Li is an IgM immunoglobulin strongly reacting in a complement-dependent cyto-
toxicity assay against L1210/Cr leukaemia and its more or less inmmunogenic sub-
lines. The specificity of the LI antibody against L1210 leukaemia was studied by
extensive screening with normal adult and foetal tissues, lymphoid tissues from
several independent strains and a panel of the most common experimental tumours,
to all of which it was unreactive. Attempts at immunotherapy were carried out in
DBA/2 mice challenged with L1210 leukaemia and treated with Li (ascites) and
complement. Although the in vitro cytotoxic titre of ascites fluid from mice bearing
hybridoma was very high (10-7), no therapeutic effect was obtained in vivo.
TUMOUR CELLS have been shown to
express surface antigens in both animal
and human experimental systems. These
include histocompatibility antigens and
tumour-associated antigens (TAA). Since
they were identified (Prehn & Main, 1957;
Klein et al., 1960; Old & Boyse, 1964),
TAA have been regarded as a natural
target for cancer immunotherapy. Yet
immunotherapy through humoral or cell-
mediated manipulations has been so far
ineffective (Rosenberg et al., 1977;
Hawrylko, 1978; Motta, 1971). The failure
of passive immunotherapy has been
ascribed to the low immunogenicity
(Hewitt et al., 1976) ofTAA, fast shedding
of antigen (Black, 1980), neutralizing
antigens circulating in the blood (Nadler
et al., 1980a) and antigenic modulation
elicited by serum itself (Boyse et al., 1967;
Stackpole et al., 1980). Although TAA
have been found in a great number of
tumour cells, they have not yet been well
characterized molecularly. Conventional
anti-tumour sera have not been com-
pletely reliable for the analysis of TAAs,
owing to their low affinity and low titre.
Since monoclonal antibodies overcome the
above limitations (Gunn et al., 1980;
Simrell & Klein, 1979; Nadler et al.,
1980b), they should provide, in principle,
an ideal means of study and treatment of
tumours immunologically. In this paper
the preparation and the characterization
of a monoclonal antibody specific to an
L1210 leukaemia-associated antigen is
reported.
The monoclonal antibody, secreted by
a mouse-mouse hybridoma, has been
obtained by fusing the mouse myeloma
P3X63/Ag8 cells and spleen cells from
mice immune to a syngeneic highly
immunogenic subline of the L1210
leukaemia.
MATERIALS AND METHODS
Mice and tumours. Inbred DBA/2, C3H,
C57BL/6J, BALB/c and hybrid CD2F1
male mice, 10-15 weeks old, were obtained
from Charles River (Calco, Italy). AKR,C. TESTORELLI, S. MORELLI, A. GOLDIN AND A. NICOLIN
B10.S male mice were kindly provided by
Dr G. Parmiani, N.C.I., Milan, Italy. Low-
immunogenic L1210/Cr leukaemia was main-
tained by weekly i.p. passage in compatible
CD2F1 mice. The immunogenic L1210/
DTIC sublines, obtained as previously de-
scribed (Mihich & Kitano, 1971; Bonmassar
et al., 1970; Nicolin et al., 1974), were grown
in CD2F1 mice immunosuppressed by 200
mg/kg cyclophosphamide i.p. 24h before
challenge. The properties of the tumour
cells used to assess the specificity of mono-
clonal antibodies are indicated in Table V
and the tumours were maintained by in
vivo or in vitro passages under standard
methods.
Hybridization.-The hybridization tech-
nique described by Nowinski et al. (1979)
has been followed, with minor modifications.
Briefly, CD2F1 mice were challenged with
107 viable L1210/DTIC cells i.p. on Days 0
and 7, and i.v. on Day 17. Three days later
spleen cells from immune mice were mixed
with BALB/c myeloma P3X63/Ag8 cells in a
ratio of 4:1 in serum-free RPMI 1640
(Eurobio, Paris, France). The mixture was
centrifuged in 50ml plastic tubes (Falcon,
Cockeysville, Md., U.S.A.) and the pellet
resuspended in 50%/ polyethylene glycol,
mol. wt 1500 (PEG 1500, Merck-Schuchardt,
Hohenbrunn, W. Germany) at 37°C. The con-
centration of PEG was gradually decreased
by the slow addition of serum-free RPMI
1640 with gentle stirring. The cell suspension
was washed and resuspended in 40 ml of
complete RPMI 1640 (20% foetal calf
serum, Seromed, Miunchen, Germany) and
distributed on 4 96-well, flat-bottomed micro-
titre plates (Falcon). On Days 1, 2, 4, 7 and
11 the culture medium was replaced with
conditioned hypoxanthine-aminopterin-thy-
midine (HAT) medium (Littlefield, 1964). Two
to three weeks after fusion, 100 ,l of culture
supernatant from wells with growing hybrids,
as seen under the microscope, were collected
for preliminary screening. Cytotoxic anti-
bodies in hybridoma cultures were detected
by the 51Cr-release assay, using 5lCr-labelled
L1210/DTIC cells as targets (Cerottini et al.,
1974). Briefly, 25 ,ul containing 106 target
cells/ml were exposed to 25 1l culture
supernatant for 30 min at 37°C. An appro-
priate dilution of rabbit complement was
added (25 ,ul) and cells were incubated for
30 min at 37°C. The mean cytotoxicity of
triplicate samples was calculated as:
51Cr released by hybridomna supernatant
- 51Cr released by control
51Cr released into detergent X 100
- 51Cr released by control
Cultures showing > 15% cytotoxicity were
scored as positive (Ozato et al., 1980).
Cloning and establishment of hybridorna
cell lines. Antibody-producing hybridoma
cultures were cloned in a 96-well microplate
by limiting dilution on a feeder layer ofmacro-
phages (0.3 to 1 cell/100lGI/well). Positive
clones were grown on a larger scale and divi-
ded into 3 pools. The first pool was stored at
- 80°C for future use, the second injected
i.p. (106 cell/mouse) into BALB/c mice
primed with tetramethylpentadecane (Pris-
tane, Schillings, Steinheim, W. Germany)
0 5 ml/mouse i.p., to obtain large amounts of
antibodies, and the last pool was maintained
in vitro.
Ig class analysis.-The inhibition of cyto-
toxic activity after incubation with goat
antisera to mouse TgM, IgGi, TgG2, IgA
immunoglobulins (Meloy Laboratories,
Springfield, Virginia) was used to identify
the heavy-chain class of the monoclonal
antibody.
Fluorescence. Normal cells or cells of
L1210/Cr leukaemia (106 cells in 0-1 ml) were
incubated with 20 ,ul of monoclonal antibody
(supernatant of Clone EIO diluted 1:64) for
40 min in an ice bath. After washing, fluores-
cein isothiocyanate-conjugated (FITC) rabbit
anti-mouse IgG (Cappel Laboratories, Coch-
ranville, PA) was added at a 1: 10 dilution and
the tubes incubated for 30 min in an ice bath.
The cells were washed and the fluorescence
was evaluated under the 40 x lens of an
Olympus microscope with epifluorescence
optics.
RESULTS
Cell fusion and production of the mono-
clonal antibody
Two weeks after fusion, hybrid cells
weredetectedin 950 ofthewells. Although
after further growth in 24-well plates
most of them lost their activity (Nowinski
et al., 1979; Ozato et al., 1980), in the early
screening about 500 of positive super-
natants were obtained (specific 51Cr-
release 15-60%). One of 3 definitely
positive hybrids, immediately minicloned,
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TABLE I.-L1 reactivity to different sublines of L1210 leukaemia
Target cells
L1210/Cr
L1210/Ha
L1210/DTIC
L1210/Cr
(in vitro)
L1210/DTIC
(in vitro)
L1210/Crt
(Clone 2)
L1210/DTIC§
(Clone 2)
L1210/Cr
(Clone 4)
L1210/DTIC
(Clone 4)
L1210/Cr
(Clone 5)
L1210/DTIC
Immunogenicity*
+
++
+
+
+
+
% 51Cr release
(±s.e.)
80+ 1-8
75+ 1-6
78+ 1 2
12+0-2
20+0-2
76+ 1-9
77+ 1-3
68+0-9
84 + 1-5
69 + 1- 3
73+0 9
Absorbingt
capacity
5x 106
NT
5x 106
NT
NT
107
107
NT
5 x 106
107
107
* The degree of immunogenicity was established from the in vivo rejection by
DBA/2Cr mice (Nicolin et al., 1980).
t The number of tumour cells needed to absorb 50% of the cytotoxicity of Li
assayed against L1210/Cr target cells. The source of LI was the supernatant
from Clone E1O diluted 1: 128.
L1210/Cr clones were obtained by cloning the in vitro line by limiting dilution.
Clones were theninjected into CD2F1 mice and maintained in vivo byweekly passages
i.p.
§ L1210/DTIC clones were obtained by in vivo treatment of L1210/Cr clones with
DTIC, as described by Nicolin et al. (1974).
at 5 cells/well (Nowinski et al., 1979), has
yielded 95% positive hybrids. Cell culture
were allowed to grow on a larger scale and
supernatants were collected and frozen
at -80°C.
Cells from 3 positive miniclones were
further cloned by limiting dilution, with
cloning efficiency of 10-20%, to yield 20
highly cytotoxic supernatants. Since all
the supernatants showed the same pattern
of reactivity and contained a monoclonal
antibody ofIgM subclass, a single designa-
tion, namely LI, has been adopted.
Characterization of LI reactivity
As shown in Table I, Li is cytotoxic
against both L1210/Cr leukaemia and its
immunogenic sublines, and the less related
L1210/Ha leukaemia. The pattern of
reactivity is independent of the immuno-
genicity ofthe tumour lines, as established
by rejection experiments in syngeneic
mice (Kitano et al., 1972; Nicolin et al.,
1980). The reactivity of LI against L1210
leukaemia was confirmed by absorption
z
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FIG. 1.-Quantitative absorption of LI
activity by L1210 cells. LI was absorbed
with increasing numbers of L1210 cells at
4°C for 1 h. Residual cytotoxicity was
evaluated by a 51Cr-release assay using
L1210/Cr cells as targets. The absorbing
capacity was expressed as % inhibition of
LI cytotoxicity. Three different dilutions
of culture supernatant from Clone E10
were absorbed: 0 1:64, A 1: 128, O
1: 256. Absorption with P815 (DBA/2)
tumour cells was included as a negative
control ( x ).
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FIG. 2.-Titration of LI activity in culture supernatants (A) and in mouse ascites fluid (B).
The activity of LI is expressed as % specific 51Cr release from L1210/Cr targets. The activities
of clones (O,E10; A, DIO; O, G3) are shown.
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FIG. 3.-Inhibition of LI cytotoxicity by
goat antisera to mouse immunoglobulins.
An appropriate dilution of LI (1:64) was
incubated at 4°C for 45 min with different
dilutions of goat antisera to mouse Ig(7S)
(0), IgM (*), IgGI (A), IgG2 (-), and
IgA (x). The residual cytotoxicity of
LI was measured by 51Cr-release assay,
using L121O/Cr as targets.
tests. The cytotoxicity of LI was com-
pletely absorbed by as few as 107 tumour
cells (Fig. 1).
The titration of LI activity is shown in
Fig. 2. The cytotoxicity was much higher
in the ascitic fluid, (dilution 10-6-10-7)
than in the supernatants (dilution 10-3),
of in vitro hybridoma cultures. Hybrids
established for more than 6 months or
thawed after storage at -80°C retaine(i
their capacity to secrete LI.
The cytotoxicity of LI was completely
removed by preincubation with goat anti-oa
mouse Jg7S (ox light chains) and with goat
anti-ot mouse (Q-heavy chain) (Fig. 3).
Since a single band has been obtained by
standard immunoelectrophoresis (not
reported here) and the inhibitory effects
of other immunoglobulin subclasses were
significatively less effective, LI is con-
sidered to belong to the IgM subclass.
The specificity of LI activity for L1210
leukaemia has been established by exten-
sive screening on syngeneic and allogeneic
lymphoid cells, on normal adult and foetal
cells, and on a number of experimental
mouse tumours.
Table II shows that spleen cells from
several independent strains, both syn-
geneic and allogeneic, failed to remove LI
activity. The reactivity of LI to normal
and foetal tissues was studied by the
indirect fluorescence method. As shown in
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TABLE II.-Absorption of Li* activity
by 5 x 107 spleen cells from independent
strains
Strain Haplotype Absorptiont
DBA/2
(L1210/Cr cells) H-2d +
DBA/2
(spleen cells) H-2d
BALB/c H-2d -
CD2F1 H-2d/d -
AKR H-2k -
C3H H-2k -
C57BL/6 H-2b _
B10.S H-2s -
* The supernatant from clone El0 diluted 1:64,
assayed for cytotoxicity against 5lCr-labelled
L1210/Cr target cells, was the source of LI.
t Ability to completely absorb the LI activity,
assayed as in Fig. 1.
TABLE III.-Distribution pattern of Li
antigen on DBA/2 cell surfaces
Cell type
L1210/Cr
L1210/Ha
Spleen
Marrow
Thymus
Foetal liver
Foetal thymus
Cells staining with FITC-rabbit
anti-a-mouse IgG (%)
Treatment
Normal mouse
serum(±s.e.) LI
0-6+0-1 100+0 1
0 3+1 0 100+0-2
32+6-9 30+5-4
11-3+7-2 16-4+3-4
1-5+0-2 1-3+0-1
7-3+1 0 8-0+0-1
2-3+0-8 4-0+0-9
% 51Cr release by
rabbit anti-o-
mouse serum LI
B-enriched 78-0+0-9 1-0+0-1
population*
* B-enriched population was obtained by treating
DBA/2 spleen cells with a-Thy-1.2 antiserum and
rabbit complement. Viable cells were harvested after
separation on an Isopaque/Ficoll gradient. B-
enriched spleen cells were labelled with 51Cr and
used as targets in a complement-dependent cyto-
toxicity assay.
Table III, both normal and foetal tissues,
including marrow, thymus, liver and
spleen cells, were not stained. Moreoever,
since L1210 leukaemia could have origin-
ated from a B-cell lineage (Shevach et al.,
1972; Cooper et al., 1977), it was relevant
to study its reaction with B cells. A
B-enriched population, obtained by pre-
treatment of spleen cells from DBA/2
mouse with anti-Thy 1-2 serum and rabbit
TABLE IV.-Effect of Li on natural killer
(NK) activity
% 51Cr-
Effectors: release
Effector cells targets ( ± s.e.)
BALB/c spleen cells* 50:1 22 + 0-5
BALB/c spleen cells+LIt 50:1 25 + 1*3
BALB/c spleen cells 100:1 36+ 1 *2
BALB/c spleen cells+L1 100:1 34 + 0-9
* Spleen cells were incubated 30 min at 40C with
the supernatant from Clone D10 at a final dilution
of 1:32. Rabbit complement was then added and
cells were incubated for 45 min at 370C. After 2
washings, cells were assayed for cytotoxicity.
t NK activity was tested in a 4 h 51Cr-release
assay with 5lCr-labelled YAC-1 as target cells. Data
are presented as % specific lysis, according to the
formula and methods described by Cerottini (1974).
complement, was not lysed by LI (Table
III). In addition, LI did not modify the
activity of natural killer (NK) cells
(TableIV).
Finally, the reactivity of LI was
matched (Table V) in a complement-
dependent cytotoxicity testagainstseveral
lines of mouse tumours, most of them of
lymphoid origin, induced by either chem-
ical agents or oncogenic viruses. The panel
of tumour cells expressed T or B cell-
surface antigens: namely Thy, TL, Ly
antigens, immunoglobulins, Fc and C3
receptors. Moreover, the tumour cells
carried the most common structural viral
antigens or non-virionic specificities that
accompanyoncogenicvirusinfection. None
of the tumour lines reacted with LI.
Lack of reactivity against P388 and P815
tumours rules out the possibility that the
specificity recognized by LI is a surface
antigen of macrophages or mast-cells.
Furthermore, a B-lymphocyte tumour
line obtained by infection with Abelson
virus (Abelson & Rabstein, 1970) was also
completely unreactive.
Because of its high specificity and its
potent cytotoxicity in vitro, LI was used
for immunotherapeutic studies in L1210-
bearing animals. LI and rabbit comple-
ment were inoculated, following various
schedules of treatment, into leukaemic
mice challenged with L1210 cells i.p. on
Day 0, but failed to improve their life
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TABLE V.-Characteristics of tumour cells testedfor reactivity to Li
Strain of
Target cells origin
L1210/Cr DBA/2
L5178Y DBA/2
EL4 (G+) C57BL/6
EL4 (G-) C57BL/6
P388 BALB/c
P815 DBA/2
BALB/urethan 2 BALB/c
RL S 1 BALB/c
E & G2 C57BL/6
K36 AKR
LSTRA BALB/c
YC8 BALB/c
GLV C3H
Abelson BALB/c
Haplotype
H-2d
H-2d
H-2b
H-2b
H-2d
H-2d
H-2d
H-2d
H-2b
H-2k
H-2d
H-2d
H-2k
H-2d
Tumour
induction
Carcinogen
Carcinogen
Carcinogen
Carcinogen
Carcinogen
Carcinogen
Carcinogen
X-rays
Gross virus
Spontaneous
Moloney virus
Moloney virus
Gross virus
Prednisolone +
Moloney virus
Type of tumour
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Macrophage line
Mastocytoma
Sarcoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
B lymphosarcoma
TABLE VI.-Life span of L1210 leukaemic CD2F1 mice treated with Li and complement
L1*
(0-2 ml/mouse)
Days and route
of treatment
1, 3, 5 i.p.
1 i.p.
1, 3, 5 i.p.
1, 3, 5 i.v.
Rabbit
complement:
(0*4 ml/mouse)
Days and route
of treatment
1, 2, 3, 4, 5 i.p.
1 i.p.
1, 2, 3, 4, 5 i.p.
1, 3, 5 i.v.
* The ascitic fluid of pristane-primed BALB/c mice challenged with producing clones was the source of
L 1. The in vitro cytotoxicity was at 10-6 dilution.
t Checked in vitro for complement activity.
span over that of untreated animals
(Table VI).
DISCUSSION
The L1210 lymphoblastoid cell line is a
mouse lymphoma originally induced in
DBA/2 mice by exposure to methyl-
cholanthrene (Law et al., 1949). As a
consequence of several generations of
transplants carried out in different labora-
tories, L1210 sublines have been origi-
nated with different degrees of immuno-
genicity in syngeneic hosts. The line
Li210/Cr used in this study is a tumour
that is weakly immunogenic in eliciting
both in vitro immunoresponse and in
vivo rejection. Although tumour-associa-
ted antigens in transplantable tumours
have been the object of a number of
studies, their intimate features are still
quite undefined. The availability of mono-
clonal antibodies might facilitate the
biochemical and functional characteriza-
tion of TAA. In the present report we de-
scribe an IgM monoclonal antibody (LI)
strictly specific for an antigen associated
with L1210 leukaemia. The antibody (LI)
obtained from ascitic fluid has shown high
cytotoxicity at dilutions as high as
10-6-10-7. The LI antigenic specificity
was expressed by every cell in the L1210
population, all of which stained in the
indirect fluorescence assay. The L1210cells
cultured in vitro showed decreased sus-
ceptibility to LI cytotoxicity, probably
because of increased shedding of the
antigen into the supernatant (unpub-
lished observations from this laboratory).
0 51Cr release
+80
0
-3
-3
-1
0
-1
+2
-2
-1
+1
+1
+3
+1
L1210/Cr
No. of cells on
Day 0
103
103
103
103
103
105
105
Mean survival
in days
(range)
13 (12-14)
12 (12-13)
13 (11-15)
11 (9-12)
14 (14- )
10 (10- )
10 (9-12)
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Extensive screening with normal and
malignant cells ruled out any reactivity of
LI to histocompatibility antigens, to
antigens defining different subsets of
lymphoid cells and to surface determinants
of macrophages, mast cells, or marrow
cells. Moreover, LI did not recognize
foetal tissues, namely liver, thymus and
spleen, with which L1210 leukaemia might
share some differentiation antigens. Fin-
ally, a panel of laboratory tumour cells,
transformed by different mechanisms and
expressing on their surfaces a number of
antigenic determinants and receptors, did
not express the antigen recognized by LI.
The specificity of LI to L1210 leukaemia
cells was established by its lack ofreactiv-
ity with a variety of target cells and from
the schedule of hybridization (syngeneic
immunization and mouse-mouse fusion).
In spite ofthe high in vitro cytotoxicity of
LI and lack of toxicity to the host tissues,
attempts at immunotherapy of L1210
mice were unsuccessful. Other sche1ules of
treatment, not reported here, were also
ineffective. Complement inactivation in
vivo, neutralization of LI by antigens
circulating in the blood or present in the
ascitic fluid are first among the hypotheses
that should be experimentally tested in
attempts to explain the negative in vivo
findings. Antigenic modulation by LI
itself, or poor binding to target tumour
cells, might also be worth attention.
Whatever the reason for the failure of
these and other (Houston et al., 1980;
Ritz et al., 1980) preliminary attempts at
serological therapy, the exploitation of
the monoclonal antibody technology in
experimental cancer might be furthered
by studies with LI. Since L1210 leukae-
mia has been widely used over the last 30
years and there is good knowledge of its
in vivo and in vitro biological properties,
studies with this experimental model
might easily and quickly provide some
essential pieces of information. The high
specificity of LI, and its lack of reactivity
to normal tissues, might make it an
optimal tool in carrying toxic agents to
target cells or developing experimental
methodologies for highly sensitive
immunodiagnosis.
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